IntoCell, Inc. (KOSDAQ:287840)

South Korea · Delayed Price · Currency is KRW

40,150

+350 (0.88%)

At close: Apr 27, 2026

8.22% (1Y)

Market Cap	589.61B
Revenue (ttm)	2.30B
Net Income (ttm)	-10.60B
Shares Out	15.02M
EPS (ttm)	-744.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	56,427
Average Volume	70,886
Open	39,800
Previous Close	39,800
Day's Range	39,400 - 40,400
52-Week Range	21,400 - 74,900
Beta	n/a
RSI	42.09
Earnings Date	n/a

About IntoCell

IntoCell, Inc. develops protein-drug conjugates for the treatment of cancer. It develops antibody drug conjugates (ADC), fusion albumin drug conjugates, and triple conjugates. The company also develops B7-H3 ADC, which is in preclinical Phase for the treatment of solid cancers, as well as HER3 ADC, 5T4 ADC, and PSMA ADC for solid cancers. In addition, it develops Ortho-Hydroxy Protected Aryl Sulfate (OHPAS), a novel self-immolative group that designs to incorporate various functional groups for linking targeting moieties; and OHPASM Linker-toxi... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2015

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 287840

Full Company Profile

Financial Performance

In 2025, IntoCell's revenue was 2.30 billion, a decrease of -20.86% compared to the previous year's 2.91 billion. Losses were -10.60 billion, 6.97% more than in 2024.

Financial Statements

News

There is no news available yet.